Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Cash & Current Investments (2024 - 2025)

Humacyte has reported Cash & Current Investments over the past 2 years, most recently at $50.5 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $50.5 million for Q4 2025, up 12.38% from a year ago — trailing twelve months through Dec 2025 was $50.5 million (up 12.38% YoY), and the annual figure for FY2025 was $50.5 million, up 12.38%.
  • Cash & Current Investments for Q4 2025 was $50.5 million at Humacyte, up from $19.5 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for HUMA hit a ceiling of $115.5 million in Q1 2024 and a floor of $19.5 million in Q3 2025.